TreatmentsJul 17, 2023
Community update from Biogen
We are pleased to share with you the latest community update issued by Biogen.
SMA Newsroom
OtherJul 7, 2023
Community update from Roche
We are pleased to share with you the latest community update issued by Roche.
It contains the information shared at the Cure SMA Research & Clinical Care Meeting 2023 and Family Conference which took place last week.
Clinical trialsJun 30, 2023
Scholar Rock announces new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.
Scholar Rock announces new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.
OdySMAJun 8, 2023
Publication of OdySMA abstract in the Orphanet Journal of Rare Diseases
We are delighted to see that the OdySMA abstract submitted after the European Conference on Rare Diseases (ECRD) 2022, was recently published in the Orphanet Journal of Rare Diseases on Friday, 2nd June.